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Yeast prions: Bungee cord domains’ balancing act
Peter T. Lansbury, Jr.
The yeast prion-like protein Sup35 has repeats
responsible for the reversible induction of an altered,
but advantageous phenotype. The expansion of similar
repeat domains in several mammalian proteins is
associated with neurodegenerative disease — so why
are these ‘bungee cord’ domains conserved?
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In 1994, Reed Wickner [1] proposed that two well-
characterized non-Mendelian traits in yeast, known as
[PSI+] and [URE3], are inherited via a self-propagating
‘protein-only’ mechanism. Wickner coined the term
‘yeast prion’ to suggest an analogy between these phe-
nomena and the proposed mode of transmission of mam-
malian scrapie by an infectious agent, or prion,
comprising a single protein. The protein-only hypothesis,
originally proposed to explain the unusual properties of
the infectious agent, states that an abnormal form of a
normal protein can propagate by somehow catalyzing the
conversion of the normal form into additional copies of
itself [2]. This process could be confused with viral infec-
tion in scrapie and with inheritance in yeast, both of
which typically require nucleic acid [3,4].
In the five years since Wickner’s proposal, a com-
pelling, albeit circumstantial case for protein-only trans-
mission of both [URE3] by the protein Ure2p and
[PSI+] by Sup35 (Figure 1) has been made. This case
relies primarily on correlations between the effects of
amino acid sequence changes on in vitro protein fibril-
lization with the effects on the in vivo phenotype. A
similar experimental approach to establishing the role
of the mammalian prion protein (PrP) in scrapie has not
been as successful, primarily because the in vitro con-
version of PrP to the form associated with infectivity
(PrPSc) has not been accomplished [5,6]. Instead of
assessing the effects of disease-associated mutations on
PrPSc formation, an experimentally accessible property
of PrP, its thermodynamic stability, has been examined.
But no correlation has been found between the patho-
genicity of PrP mutations and their effect on PrP sta-
bility [7,8], consistent with the proposal that PrP
fibrillization, rather than its unfolding, is accelerated by
disease-associated mutations [9,10].
One class of disease-associated insertional mutations of PrP
affect its normally unstructured amino-terminal region,
which contains five copies of a conserved octapeptide
repeat (Figure 2) [11]. Families have been identified in
which insertion of additional copies of the repeat causes
disease. Lindquist and Liu [12] recently noticed a simi-
larity between the PrP octapeptide repeat and a non-
apeptide sequence that is repeated five times in Sup35,
within an amino-terminal domain known to be critical for
its in vitro fibrillization and for induction of the associ-
ated [PSI+] phenotype (Figure 2). They went on to test
whether the Sup35 repeats mediate oligomerization
and/or fibrillization by producing two sequence variants
of Sup35, one in which two repeats were added, and the
other in which four repeats were removed. 
Lindquist and Liu [12] found that the expanded Sup35
(Exp-Sup35 in Figure 1) promoted conversion of yeast to
the [PSI+] phenotype, whereas the truncated protein
precluded appearance of the phenotype. Furthermore,
recombinant peptides based on the portion of the Sup35
sequence containing one, five or seven repeats were
shown to form amyloid fibrils at rates that paralleled the
in vivo phenotypes; that is, the expanded peptide fibril-
lized most rapidly and the truncated peptide most
slowly. These rate differences were observed starting
with chemically denatured substrates, suggesting that
the promotion of Sup35 fibrillization, rather than facilita-
tion of Sup35 unfolding, is the mechanism whereby
some or all of the insertional mutations exert their
effects. The authors suggest that this may also be the
Figure 1
Mechanism proposed to explain the association between yeast [psi–]
and [PSI+] phenotypes and the oligomeric state of Sup35 [1,3].
Oligomeric structures may  be amyloid fibrils, but the intermolecular
orientation shown is for illustrative purposes only. Fibril formation (and
phenotype switching) can be seeded by preexisting fibrils, which
explains transmission of the [PSI+] trait by cytoplasmic inheritance. The
artificial repeat-expanded protein Exp-Sup35 [12] promotes formation
of the [PSI+] phenotype (the red bar denotes the repeat array).
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case for the PrP insertion mutations, as well as other PrP
mutations associated with prion diseases [12].
A different approach to identifying the sequence within
Sup35 that promotes the [PSI+] phenotype was taken by
Weissman and coworkers [13] and inspired an analogy
between the yeast prion-like elements and the ‘triplet
repeat’ class of neurodegenerative diseases, of which Hunt-
ington’s disease is perhaps the most notorious. A Sup35
fragment was randomly mutagenized and yeast colonies
were then screened for loss of the preexisting [PSI+] pheno-
type, or gain of the alternative phenotype. Forty-one mutant
sequences were determined, each of which was found to
contain point mutations in the region between residues 8
and 24 at the extreme amino-terminus of Sup35 (Figure 2). 
This region of Sup35 contains two of the nonapeptide
repeats discussed above. Thirty-four of the 41 mutations
involved changes of asparagine or glutamine residues,
primarily (32 out of the 34 cases) to charged amino acids.
Six of these mutations were introduced into a fibrillo-
genic Sup35 fragment; four decreased the rate of its
fibrillogenesis, while the other two had no significant
effect. Weissman and colleagues [13] proposed that it is
the high local concentration of glutamine and asparagine
residues — distinguished by their amide side chains,
which can promote unusual structures [14] — that drives
fibrillization of the amino-terminal region of Sup35. Fur-
thermore, they suggested an analogy between the aggre-
gation Sup35 and that of huntingtin (Htn), which is
promoted by an expansion of a preexisting polyglutamine
tract that is associated with Huntington’s disease
(Figure 1) [15]. To emphasize this analogy, a construct in
which the entire Sup35(8–24) sequence was replaced by
glutamine residues was shown to form insoluble aggre-
gates in yeast, similar to those formed by wild-type Sup 35
in [PSI+] yeast [13].
Huntington’s disease is caused by an expansion of a
preexisting tract of glutamine residues in Htn from the
normal range of 6–35 residues to anywhere between 36
and 121 glutamine residues [15]. The length of the
expansion is correlated to the age of onset and severity of
symptoms, with particularly long polyglutamine tracts
causing juvenile-onset disease. Recombinant peptides
based on the disease-associated expanded polyglutamine
tract, form amyloid fibrils in vitro that resemble those
found in neuronal intranuclear inclusions characteristic of
the Huntington’s disease brain [16]. The rate of in vitro
amyloid formation depends on the length of the polygluta-
mine tract, supporting a correlation between fibril forma-
tion and disease and suggesting that the Htn fibril, or an
oligomeric species whose formation is linked to that of the
fibril, may be pathogenic in Huntington’s disease. The
Sup35/PrP/Htn analogy is imperfect, however, as there is
no evidence that Huntington’s disease can be transmitted
by Htn fibrils, though seeding of in vitro fibril formation
by preformed model peptide fibrils does occur [16].
Lindquist [3] has suggested that the fibrillization of Sup35
may provide a useful adaptive mechanism to change gene
expression patterns in response to rapid environmental
changes. In that capacity, it would be important for the
[psi–] to [PSI+] ‘switch’ to be reversible, in the event of a
return to the original conditions (Figure 1). Fibrillization
of Sup35 may thus have been ‘adjusted’ by evolution to
achieve optimal rates in the forward and reverse direc-
tions. Inclusion of seven nonapeptide repeats, rather than
five, may slow down the back reaction to the extent that
spontaneous loss of the [PSI+] phenotype would be too
slow, whereas inclusion of only two repeats may slow
down the forward reaction to the extent that spontaneous
acquisition of the [PSI+] phenotype would not occur often
enough to provide an evolutionary advantage.
Given the possibility of fibrillization, why do the pro-
teins involved in neurodegenerative diseases also contain
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Figure 2
The yeast prion-like protein Sup35 and two other proteins that contain
repeating sequences (red) and are involved in neurodegenerative
diseases. Huntingtin (Htn) is one representative of a large class of
proteins that contain expandable polyglutamine tracts [15]. The normal
repeat lengths are shown; expansion leads to altered phenotype in the
case of yeast Sup35 and disease in the case of the PrP and Htn. The
normal functions of PrP and Htn are not known.
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A mechanistic proposal to explain the persistence of expandable
repeat sequences (‘bungee cord’ domains) in proteins involved in
neurodegenerative diseases. According to this scenario, the normal
function of these proteins may depend on the repeat sequence,
creating an evolutionary rationale for retaining sequences that, when
expanded, promote fibrillization.
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expandable repeat domains that put the protein ‘at risk’
of pathogenic insertional mutation? One possible expla-
nation is that these conserved repeats may be important
for the normal, as yet unknown, functions of these pro-
teins. The length of the normal repeat domain may be
a compromise between optimization of that function
and minimization of early-onset disease (Figure 3).
The repeat domains may directly mediate functional
oligomerization, as appears to be the case with Sup35
and Htn, or may do so indirectly (Figure 3). This would
explain why evolution has not eliminated an existing
mechanism for polyglutamine expansion by which repeat
lengths can increase — and the associated disease appear
earlier — in successive generations. This phenomenon,
known as anticipation, may be the pathogenic conse-
quence of an adaptive mechanism that allows the func-
tion–dysfunction balance point to be reset after rapid
environmental change.
I propose the term ‘bungee cord domains’ to describe
these sequences, as the selection of an ideal bungee cord
is based on its length and involves a compromise
between the intended function of the jump (presumably
the thrill of a close call) with a desire to minimize the
risk of death (the risk of injury, like that of late-onset
disease, may be tolerated). In addition to PrP and the
polyglutamine-containing proteins, the Parkinson’s
disease-related protein α-synuclein [17], which contains
six copies of an undecapeptide repeat that has been
implicated in membrane binding, and the Alzheimer’s
disease-related protein tau, which contains three or four
repeats that are involved in microtubule binding, may
belong in this class. As the normal functions of these pro-
teins are elucidated and their bioactive oligomerization
states are determined, the bungee cord proposal will be
put to the test. One critical consequence of this proposal
— that inhibition of pathogenic fibrillization may also
inhibit a critical normal function — should be noted by
those interested in development of therapeutic strategies
against neurodegenerative diseases.
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